Suppr超能文献

尼美舒利与布洛芬对骨关节炎急性发作患者尿中II型胶原C末端肽降解产物水平以及血清中透明质酸、基质金属蛋白酶-3和-13水平的比较效应

Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis.

作者信息

Manicourt Daniel-Henri, Bevilacqua Maurizio, Righini Velella, Famaey Jean-Pierre, Devogelaer Jean-Pierre

机构信息

Department of Rheumatology, Université Catholique de Louvain, Saint-Luc University Hospital Saint-Luc, Brussels, Belgium.

出版信息

Drugs R D. 2005;6(5):261-71. doi: 10.2165/00126839-200506050-00002.

Abstract

BACKGROUND AND AIM

Because in vitro studies have shown that nimesulide not only preferentially inhibits COX-2 but also reduces the action/release of pro-inflammatory cytokines, down-regulates the synthesis and/or activity of collagenase(s), and releases reactive oxygen species and other toxic substances from neutrophils, this study investigated whether nimesulide and ibuprofen could affect levels of biochemical markers of joint inflammation and collagen catabolism in patients with flare-up of knee or hip osteoarthritis.

METHODS

Ninety patients were included in this randomised, prospective, single- blind study. They received either nimesulide (n = 45) or ibuprofen (n = 45) for a 4-week treatment period. The following parameters were analysed by ELISA: urinary levels of C-terminal cross-linking telopeptide of type II collagen (CTX-II), a marker of type II collagen breakdown; serum levels of hyaluronan (HA), a marker of synovial inflammation and hyperplasia; and circulating levels of stromelysin-1 (matrix metalloproteinase-3 [MMP-3]), collagenase-1 (MMP-1) and collagenase-3 (MMP-13). Statistical analysis used was ANOVA.

RESULTS

At the end of the treatment period, nimesulide but not ibuprofen markedly reduced the urinary levels of CTX-II (p < 0.001) and the serum levels of HA (p < 0.05), two markers known to prognosticate poor outcome of the osteoarthritis disease process. Nimesulide also reduced the serum levels of both MMP-3 (p < 0.05) and MMP-13 (p < 0.001). Furthermore, in the nimesulide group, the decrease in levels of CTX-II correlated significantly with the decrease in levels of HA and MMP-13.

CONCLUSION

Although nonsteroidal anti-inflammatory drugs are effective in improving pain and disability in OA patients, to date it has been unclear to what extent these drugs could affect joint metabolism and hence joint structure. Patients with flare-up of their osteoarthritis disease process exhibit enhanced levels of markers of joint inflammation and cartilage collagen breakdown, which were markedly decreased by nimesulide but not by ibuprofen.

摘要

背景与目的

由于体外研究表明尼美舒利不仅能优先抑制环氧化酶-2(COX-2),还能减少促炎细胞因子的作用/释放,下调胶原酶的合成和/或活性,并从中性粒细胞释放活性氧和其他有毒物质,本研究调查了尼美舒利和布洛芬是否会影响膝关节或髋关节骨关节炎急性发作患者关节炎症和胶原分解代谢的生化标志物水平。

方法

90例患者纳入了这项随机、前瞻性、单盲研究。他们接受尼美舒利(n = 45)或布洛芬(n = 45)治疗4周。通过酶联免疫吸附测定(ELISA)分析以下参数:II型胶原C端交联末肽(CTX-II)的尿水平,这是II型胶原降解的标志物;透明质酸(HA)的血清水平,这是滑膜炎症和增生的标志物;以及基质溶解素-1(基质金属蛋白酶-3 [MMP-3])、胶原酶-1(MMP-1)和胶原酶-3(MMP-13)的循环水平。所采用的统计分析方法为方差分析(ANOVA)。

结果

在治疗期结束时,尼美舒利而非布洛芬显著降低了CTX-II的尿水平(p < 0.001)和HA的血清水平(p < 0.05),这两个标志物已知可预示骨关节炎疾病进程的不良结局。尼美舒利还降低了MMP-3(p < 0.05)和MMP-13的血清水平(p < 0.001)。此外,在尼美舒利组中,CTX-II水平的降低与HA和MMP-13水平的降低显著相关。

结论

尽管非甾体抗炎药在改善骨关节炎患者的疼痛和功能障碍方面有效,但迄今为止尚不清楚这些药物在多大程度上会影响关节代谢进而影响关节结构。骨关节炎疾病进程急性发作的患者表现出关节炎症和软骨胶原分解标志物水平升高,尼美舒利可使其显著降低,而布洛芬则无此作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验